# Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia

> **NCT00510939** · PHASE2 · UNKNOWN · sponsor: **University of Bologna** · enrollment: 72 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Tipifarnib plus Bortezomib

## Key facts

- **NCT ID:** NCT00510939
- **Lead sponsor:** University of Bologna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2009-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00510939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00510939, "Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00510939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*